Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway
Yu Liang,Lidan Hou,Linjing Li,Lei Li,Liming Zhu,Yu Wang,Xin Huang,Yichao Hou,Danxi Zhu,Huimin Zou,Yan Gu,Xiaoling Weng,Yingying Wang,Yue Li,Tianqi Wu,Mengfei Yao,Isabelle Gross,Christian Gaiddon,Meng Luo,Jianhua Wang,Xiangjun Meng
DOI: https://doi.org/10.1038/s41388-019-1035-8
IF: 8.756
2019-10-09
Oncogene
Abstract:Abstract The development of chemoresistance remains a major challenge that accounts for colorectal cancer (CRC) lethality. Dichloroacetate (DCA) was originally used as a metabolic regulator in the treatment of metabolic diseases; here, DCA was assayed to identify the mechanisms underlying the chemoresistance of CRC. We found that DCA markedly enhanced chemosensitivity of CRC cells to fluorouracil (5-FU), and reduced the colony formation due to high levels of apoptosis. Using the microarray assay, we noted that miR-149-3p was involved in the chemoresistance of CRC, which was modulated by wild-type p53 after DCA treatment. In addition, PDK2 was identified as a direct target of miR-149-3p. Mechanistic analyses showed that overexpression of miR-149-3p enhanced 5-FU-induced apoptosis and reduced glucose metabolism, similar to the effects of PDK2 knockdown. In addition, overexpression of PDK2 partially reversed the inhibitory effect of miR-149-3p on glucose metabolism. Finally, both DCA treatment and miR-149-3p overexpression in 5-FU-resistant CRC cells were found to markedly sensitize the chemotherapeutic effect of 5-FU in vivo, and this effect was also validated in a small retrospective cohort of CRC patients. Taken together, we determined that the p53/miR-149-3p/PDK2 signaling pathway can potentially be targeted with DCA treatment to overcome chemoresistant CRC.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology